This news section provides a round-up of our latest news and developments. We also intend to add helpful articles and tips to help you improve your approach to pharmaceutical related artwork management.
The Falsified Medicines Directive 2011/62/EU, which is due for adoption in February 2019, will require pharmaceutical companies to apply serialisation codes to every applicable pack (OTC and some minor exemptions). As a consequence, artwork changes will be required, which all too often are treated as a rushed after-thought.
Cirrus, the specialist artwork management service for healthcare packaging, has just successfully completed Yellow Belt training for all its employees as part of a Go Lean Six Sigma programme.
The World Health Organisation estimates that around 50% of product recalls are attributed to artwork errors and mislabeling. The industry's 'speed to market' requirements have put more pressure on artwork teams across all aspects of the supply chain to deliver 'right first time' and 'on-time' for critical product launches. This has inevitably meant the risk from errors is much higher.
Cirrus, a Multi Packaging Solutions company, offers a full artwork management service ahead of enforced pack changes due to impending legislation. The Falsified Medicines Directive 2011/62/EU, which is due for adoption in February 2019, will require many companies to apply serialisation codes to their packaging. As a consequence, artwork changes will be required which all too often are treated as a rushed after-thought.
Historically, artwork for the packaging and labeling of pharmaceutical products has been the final part of a long process to get a product ready for market. All too often, it was treated as a rushed after-thought.
We have a thorough understanding of the complex regulatory environment and unique requirements.
By partnering with all stakeholders during this stage, we ensure data integrity, process efficiency, error elimination and reduced artwork cycle times.